Evidence map›Paper›PMID 26983599›Full record

ArticleScientific reports2016

Metabolic role of dipeptidyl peptidase 4 (DPP4) in primary human (pre)adipocytes.

Pia Zilleßen, Jennifer Celner, Anita Kretschmann, Alexander Pfeifer, Kurt Racké, Peter Mayer

Open access · goldAbstract read
In one paragraph

Article in Scientific reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
3.2field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 69 citations in OpenAlex.

  1. Article
  2. Article
  3. Developmental origins of immunometabolic health.Immunometabolism (Cobham, Surrey) · 2026
    Review
  4. Article
  5. Article
  6. Integrating network analysis and machine learning to elucidate chemical-induced pancreatic toxicity in zebrafish embryos.Toxicological sciences : an official journal of the Society of Toxicology · 2025
    Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Pia ZilleßenFederal Institute for Drugs and Medical Devices (BfArM), 53175 Bonn, Germany.
Jennifer CelnerFederal Institute for Drugs and Medical Devices (BfArM), 53175 Bonn, Germany.
Anita KretschmannInstitute for Pharmacology and Toxicology, University of Bonn, 53105 Bonn, Germany.
Alexander PfeiferInstitute for Pharmacology and Toxicology, University of Bonn, 53105 Bonn, Germany.
Kurt RackéInstitute for Pharmacology and Toxicology, University of Bonn, 53105 Bonn, Germany.
Peter MayerFederal Institute for Drugs and Medical Devices (BfArM), 53175 Bonn, Germany.
Federal Institute for Drugs and Medical Devices · DEUniversity of Bonn · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Dipeptidyl peptidase 4 (DPP4) is the target of the gliptins, a recent class of oral antidiabetics. DPP4 (also called CD26) was previously characterized in immune cells but also has important metabolic functions which are not yet fully understood. Thus, we investigated the function of DPP4 in human white preadipocytes and adipocytes. We found that both cell types express DPP4 in high amounts; DPP4 release markedly increased during differentiation. In preadipocytes, lentiviral DPP4 knockdown caused significant changes in gene expression as determined by whole-genome DNA-array analysis. Metabolic genes were increased, e.g. PDK4 18-fold and PPARγC1α (=PGC1α) 6-fold, and proliferation-related genes were decreased (e.g. FGF7 5-fold). These effects, contributing to differentiation, were not inhibited by the PPARγ antagonist T0070907. Vice versa, the PPARγ agonist pioglitazone induced a different set of genes (mainly FABP4). DPP4 knockdown also affected growth factor signaling and, accordingly, retarded preadipocyte proliferation. In particular, basal and insulin-induced ERK activation (but not Akt activation) was markedly diminished (by around 60%). This indicates that DPP4 knockdown contributes to adipocyte maturation by mimicking growth factor withdrawal, an early step in fat cell differentiation. In mature adipocytes, DPP4 becomes liberated so that adipose tissue may constitute a relevant source of circulating DPP4.

Indexed as

AdipocytesAdipose Tissue, WhiteBenzamidesCell DifferentiationCells, CulturedDipeptidyl Peptidase 4Extracellular Signal-Regulated MAP KinasesFatty Acid-Binding ProteinsHumansInsulinMicroscopy, Electron, ScanningMicroscopy, FluorescenceOligonucleotide Array Sequence AnalysisPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPioglitazonePPAR gammaBenzamidesDipeptidyl Peptidase 4Extracellular Signal-Regulated MAP KinasesFABP4 protein, humanFatty Acid-Binding ProteinsInsulinPDK4 protein, humanPeroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alphaPioglitazonePPAR gammaPPARGC1A protein, humanProtein Serine-Threonine KinasesPyridinesPyruvate Dehydrogenase Acetyl-Transferring KinaseRNA, Small InterferingT 0070907Thiazolidinediones

Identifiers

PMID26983599
PMCPMC4794806
OpenAlexW2330263046

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.